boron has been researched along with Skin-Neoplasms* in 15 studies
1 review(s) available for boron and Skin-Neoplasms
Article | Year |
---|---|
Boron neutron capture therapy of cancer.
Topics: Animals; Antibodies, Monoclonal; Boron; Brain Neoplasms; Humans; Isotopes; Melanoma; Mice; Neutrons; Nuclear Reactors; Pharmaceutical Vehicles; Rats; Skin Neoplasms | 1990 |
4 trial(s) available for boron and Skin-Neoplasms
Article | Year |
---|---|
First BNCT treatment of a skin melanoma in Argentina: dosimetric analysis and clinical outcome.
A Phase I/II protocol for treating cutaneuos melanomas with BNCT was designed in Argentina by the Comisión Nacional de Energía Atómica and the medical center Instituto Roffo. The first of a cohort of thirty planned patients was treated on October 9, 2003. This article depicts the protocol-based procedure and describes the first clinical case, treatment regime and planning, patient irradiation, retrospective dosimetric analysis and clinical outcome. Considering the low acute skin toxicity and the complete response in 21 of the 25 subcutaneous melanoma nodules treated, a second irradiation was performed in a different location of the extremity of the same patient. The corresponding clinical outcome is still under evaluation. Topics: Argentina; Boron; Boron Compounds; Boron Neutron Capture Therapy; Clinical Protocols; Female; Fructose; Humans; Melanoma; Middle Aged; Radiotherapy Planning, Computer-Assisted; Skin Neoplasms; Treatment Outcome | 2004 |
Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor.
Twenty-two patients with malignant melanoma were treated with boron neutron capture therapy (BNCT) using 10B-p-boronophenylalanine (BPA). The estimation of absorbed dose and optimization of treatment dose based on the pharmacokinetics of BPA in melanoma patients is described. The doses of gamma-rays were measured using small TLDs of Mg2SiO4 (Tb) and thermal neutron fluence was measured using gold foil and wire. The total absorbed dose to the tissue from BNCT was obtained by summing the primary and capture gamma-ray doses and the high LET radiation doses from 10B(n, alpha)7Li and 14N(n,p)14C reactions. The key point of the dose optimization is that the skin surrounding the tumour is always irradiated to 18 Gy-Eq, which is the maximum tolerable dose to the skin, regardless of the 10B-concentration in the tumor. The neutron fluence was optimized as follows. (1) The 10B concentration in the blood was measured 15-40 min after the start of neutron irradiation. (2) The 10B-concentration in the skin was estimated by multiplying the blood 10B value by a factor of 1.3. (3) The neutron fluence was calculated. Absorbed doses to the skin ranged from 15.7 to 37.1 Gy-Eq. Among the patients, 16 out of 22 patients exhibited tolerable skin damage. Although six patients showed skin damage that exceeded the tolerance level, three of them could be cured within a few months after BNCT and the remaining three developed severe skin damage requiring skin grafts. The absorbed doses to the tumor ranged from 15.7 to 68.5 Gy-Eq and the percentage of complete response was 73% (16/22). When BNCT is used in the treatment of malignant melanoma, based on the pharmacokinetics of BPA and radiobiological considerations, promising clinical results have been obtained, although many problems and issues remain to be solved. Topics: Aged; Aged, 80 and over; Boron; Boron Neutron Capture Therapy; Dose-Response Relationship, Radiation; Female; Humans; Isotopes; Male; Melanoma; Middle Aged; Radiation Injuries; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Skin; Skin Neoplasms; Treatment Outcome | 2003 |
A pharmacokinetic model for the concentration of 10B in blood after boronophenylalanine-fructose administration in humans.
An open two-compartment model has been developed for predicting (10)B concentrations in blood after intravenous infusion of the l-p-boronophenylalanine-fructose complex (BPA-F) in humans and derived from studies of pharmacokinetics in 24 patients in the Harvard-MIT Phase I clinical trials of BNCT. The (10)B concentration profile in blood exhibits a characteristic rise during the infusion to a peak of approximately 32 microg/g (for infusion of 350 mg/kg over 90 min) followed by a biphasic exponential clearance profile with half-lives of 0.34 +/- 0.12 and 9.0 +/- 2.7 h, due to redistribution and primarily renal elimination, respectively. The model rate constants k(1), k(2) and k(3) are 0.0227 +/- 0.0064, 0.0099 +/- 0.0027 and 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution, V(1), is 0.235 +/- 0.042 kg/kg. The validity of this model was demonstrated by successfully predicting the average pharmacokinetic response for a cohort of patients who were administered BPA-F using an infusion schedule different from those used to derive the parameters of the model. Furthermore, the mean parameters of the model do not differ for cohorts of patients infused using different schedules. Topics: Adult; Aged; Boron; Boron Compounds; Boron Neutron Capture Therapy; Brain Neoplasms; Female; Fructose; Glioblastoma; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Models, Biological; Phenylalanine; Skin Neoplasms | 2001 |
Selective thermal neutron capture therapy and diagnosis of malignant melanoma: from basic studies to first clinical treatment.
Topics: Boron; Clinical Trials as Topic; Gamma Rays; Humans; Isotopes; Melanoma; Neutrons; Radiotherapy; Radiotherapy Dosage; Skin Neoplasms | 1989 |
10 other study(ies) available for boron and Skin-Neoplasms
Article | Year |
---|---|
Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT).
Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using 10B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86 years at the time of treatment. All of the targets were primary lesions and they were located on the sole or face. No patient had evidence of regional lymph node involvement, distant metastases or an active secondary cancer. The clinical stage was cT1-2N0M0 and performance scores were <2. BNCT was carried out at the Kyoto University Research Reactor (KUR). The patients were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin dose. Eight patients were evaluated and six showed a complete response (CR), while two patients had a partial response (PR). Of the two patients with a PR, one has remained a PR with brown spots persisting for 7.5 years following BNCT. The tumor in the other patient recurred after 6 years at the site of persisting brown macula. The overall control rate (CR + PR without recurrence) for the cohort was 88% (7/8). There have never been any adverse events >Grade 2 for the long follow-up period. Our results suggest that BNCT may be a promising treatment modality in the management of early stage cutaneous melanoma when wide local excision is not feasible. Topics: Aged; Aged, 80 and over; Boron; Boron Neutron Capture Therapy; Female; Follow-Up Studies; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Neoplasm Recurrence, Local; Radiation Dosage; Radiometry; Radiotherapy Dosage; Skin Neoplasms; Treatment Outcome | 2020 |
Experimental Studies of Boronophenylalanine ((10)BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment.
Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina ((10)BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis.. The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 10(6) MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples.. The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of (10)B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37 °C and 23 °C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R(2) = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R(2) = 0.81, logistic function fit).. We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT treatment for each individual patient and lesion. Topics: Animals; Body Temperature; Boron; Boron Compounds; Boron Neutron Capture Therapy; Cell Line, Tumor; Humans; Ki-67 Antigen; Melanoma; Melanoma, Cutaneous Malignant; Mice; Mice, Nude; Phenylalanine; Platelet Endothelial Cell Adhesion Molecule-1; Radioisotopes; Skin Neoplasms; Tissue Distribution; Tumor Burden | 2015 |
A novel 10B-enriched carboranyl-containing phthalocyanine as a radio- and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies.
The synthesis of a Zn(ii)-phthalocyanine derivative bearing four 10B-enriched o-carboranyl units (10B-ZnB4Pc) and its natural isotopic abundance analogue (ZnB4Pc) in the peripheral positions of the tetraazaisoindole macrocycle is presented. The photophysical properties of ZnB4Pc, as tested against model biological systems, were found to be similar with those typical of other photodynamically active porphyrin-type photosensitisers, including a singlet oxygen quantum yield of 0.67. The carboranyl-carrying phthalocyanine was efficiently accumulated by B16F1 melanotic melanoma cells in vitro, appeared to be partitioned in at least some subcellular organelles and, upon red light irradiation, induced extensive cell mortality. Moreover, ZnB4Pc, once i.v.-injected to C57BL/6 mice bearing a subcutaneously transplanted pigmented melanoma, photosensitised an important tumour response, provided that the irradiation at 600-700 nm was performed 3 h after the phthalocyanine administration, when appreciable concentrations of ZnB4Pc were still present in the serum. Analogously, irradiation of the 10B-ZnB4Pc-loaded pigmented melanoma with thermal neutrons 24 h after injection led to a 4 day delay in tumour growth as compared with control untreated mice. These results open the possibility to use one chemical compound as both a photosensitising and a radiosensitising agent for the treatment of tumours by the combined application of photodynamic therapy and boron neutron capture therapy. Topics: Animals; Boron; Boron Neutron Capture Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Female; In Vitro Techniques; Indoles; Isoindoles; Isotopes; Liposomes; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Molecular Structure; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms; Structure-Activity Relationship; Time Factors | 2006 |
Melanogenesis investigation leading to selective melanoma neutron capture therapy and diagnosis.
Basic investigation into the nature of melanin monomer and polymer synthesis in pigment cells has revealed many of the new underlying factors involved in its regulation and control by three melanogenesis-related genes, tyrosinase, TRP-1 and TRP-2, and other non-tyrosinase glycoproteins. Pigment cells can undergo clinically and biologically recognizable progressive multi-step carcinogenesis. Generally parallel to this progressive cancerization is accentuated melanogenesis. Using this accentuated melanogenesis to develop a specific diagnosis and cure for melanoma (Mm) has long been a challenge. However, until recently, no success was achieved. As an example, attempting to utilize the fact that dopa accumulates as a melanin substrate within Mm cells, hybrid compounds of dopa and cytotoxic drugs were developed. However, these compounds were found to have severe systemic side effects and were therefore unusable. Another newer Mm treatment involves high energy radiation such as fast neutrons. But this is quite non-selective, killing both the target cancer and the normal surrounding tissue. Since 1972, I have developed the idea of coupling the high energy releasing system of thermal neutron irradiation with the non-toxic 10B-dopa analogue, 10B1-L-p-boronophenylalanine (10B1-L-BPA). Thermal neutrons are essentially harmless, but, after specific absorption by 10B, release high LET alpha-particles and 7Li-atoms with an energy of 2.33 MeV up to a distance of 14 mu, the diameter of Mm cells, thus selectively killing them without damaging surrounding normal tissue. After the synthesis of 10B1-L-BPA, exhaustive in vitro and in vivo radiological studies on its enhanced killing effect were done to develop optimal Mm Boron Neutron Capture Therapy (NCT).(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Aged; Animals; Boron; Cricetinae; Female; Humans; Isotopes; Melanins; Melanocytes; Melanoma; Neutron Capture Therapy; Skin Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 1994 |
The potential of neutron capture therapy in the management of uncontrollable localised tumours.
The role of Neutron Capture Therapy for the treatment of uncontrollable, localised tumours is examined. Several boron carrier biochemicals are already in use for the selective accumulation of boron in cancer cells, and therapeutic boron concentrations have been achieved in glioblastoma and melanoma in animal models and in patients. Local control of glioblastoma and subcutaneous melanoma has been reported after thermal neutron irradiation. Different neutron beam requirements apply for the treatment of these cancers, in the former case a thermal beam is adequate but a more penetrating epithermal beam is needed for the treatment of deep-seated tumours. A thermal facility for small animal irradiations is available in Australia, and the development of a patient thermal/epithermal facility is under active consideration. Topics: Boron; Boron Compounds; Brain Neoplasms; Glioblastoma; Humans; Isotopes; Melanoma; Neutrons; Skin Neoplasms | 1990 |
In situ detection of cutaneous melanoma by prompt gamma-ray spectrometry using melanoma-seeking 10B-dopa analogue.
10B1-para-boronophenylalanine (10B1-BPA), one of our boronated dopa analogues developed for thermal neutron capture therapy, has been found to have a selective affinity for malignant melanoma. We have established a method of 'in situ' detection of subcutaneous melanoma lesions, using this melanoma-seeking 10B-labeled compound. In this study, we applied an 'in situ' 10B microanalysis system via detection of the prompt gamma-ray from the 10B(n, alpha)7Li reaction triggered by irradiating the 10B-containing target with pure thermal neutrons, called prompt gamma-ray spectrometry, to hamsters bearing Greene's melanoma in subcutis and to a human patient whose occipital subcutaneous tumor was suspected of being a metastatic melanoma. In the hamsters, the time-dependent 10B dynamics showed increased 10B accumulation in melanoma, after 10B1-BPA administration, in contrast to that in non-melanoma normal skin. In the human patient, after subcutaneous injection of 10B1-BPA into perilesional sites 4 cm distant from the tumor margin, the average 10B concentration in the tumor was determined to be 24 ppm (microgram/g), in contrast to 3 ppm in skin covering the tumor and 1.1 ppm in blood, indicative of selectively high 10B1-BPA uptake by the tumor. Topics: Aged; Animals; Boron; Boron Compounds; Cricetinae; Disease Models, Animal; Female; Humans; Isotopes; Male; Melanoma; Mesocricetus; Phenylalanine; Skin Neoplasms; Spectrometry, Gamma; Time Factors | 1990 |
Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound.
Topics: Aged; Aged, 80 and over; Boron; Foot Diseases; Humans; Isotopes; Male; Melanoma; Neutrons; Radiotherapy Dosage; Scalp; Skin Neoplasms | 1989 |
Boron neutron capture therapy of a murine melanoma.
Boron neutron capture therapy has been carried out on BALB/c mice carrying the Harding-Passey melanoma s.c. on the thigh. p-Boronophenylalanine (BPA), a boronated analogue of natural melanin precursors, was used to target boron selectively to melanoma. BPA was administered to the mice either via i.p. injection or p.o. by intubation. 10B concentrations in tumor ranged from 15 to 40 ppm depending on the route and timing of administration. Irradiations with a predominantly thermal neutron beam were performed at the Brookhaven Medical Research Reactor. In the absence of BPA, only transient tumor growth delays were observed at low neutron fluences. At 5 x 10(16) n/m2, 4 of 22 tumors irradiated in the absence of BPA underwent long-term tumor growth control; after p.o. administration of BPA (40 ppm 10B in the tumor), the fraction of tumors controlled increased to 11 of 19. The average dose to the tumor in the latter group was 17.8 Gy, of which 14.8 Gy were due to the 10B neutron capture reaction. The biological effectiveness of the absorbed dose from the neutron capture reaction, at the 50% tumor control level, was found to be twice that of 100 kVp X-rays. Topics: Animals; Boron; Female; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Neutrons; Radiotherapy Dosage; Skin Neoplasms | 1988 |
[Selective affinity of 10B1-paraboronophenylalanine-HCl to malignant melanoma: thermal neutron capture therapy].
Topics: Animals; Boron; Boron Compounds; Cricetinae; Isotopes; Melanoma; Neoplasms, Experimental; Neutrons; Phenylalanine; Skin; Skin Neoplasms; Spectrometry, Gamma | 1983 |
Thermal neutron capture therapy of malignant melanoma: in vitro radiobiological analysis.
Topics: Alpha Particles; Animals; Boron; Cell Line; Cell Survival; Chlorpromazine; Dose-Response Relationship, Radiation; Evaluation Studies as Topic; Fast Neutrons; Gamma Rays; Melanins; Melanoma; Mice; Neoplasms, Experimental; Radiotherapy; Skin Neoplasms | 1980 |